Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples. Methods: Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: < 1%, 1%–49%, and ≥ 50%. Results: The intraclass correlation coefficient for TPS was 0.902 ± 0.058. Weighted κ coefficient for 3-step assessment was 0.748 ± 0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type. Conclusions: Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.
Abstract
Background: Assessment of programmed cell death-ligand 1 (PD-L1) immunohistochemical staining is used for treatment decisions in non-small cell lung cancer (NSCLC) regarding use of PD-L1/programmed cell death protein 1 (PD-1) immunotherapy. The reliability of the PD-L1 22C3 pharmDx assay is critical in guiding clinical practice. The Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists investigated the interobserver reproducibility of PD-L1 staining with 22C3 pharmDx in NSCLC samples. Methods: Twenty-seven pathologists individually assessed the tumor proportion score (TPS) for 107 NSCLC samples. Each case was divided into three levels based on TPS: < 1%, 1%–49%, and ≥ 50%. Results: The intraclass correlation coefficient for TPS was 0.902 ± 0.058. Weighted κ coefficient for 3-step assessment was 0.748 ± 0.093. The κ coefficients for 1% and 50% cut-offs were 0.633 and 0.834, respectively. There was a significant association between interobserver reproducibility and experience (formal PD-L1 training, more experience for PD-L1 assessment, and longer practice duration on surgical pathology), histologic subtype, and specimen type. Conclusions: Our results indicate that PD-L1 immunohistochemical staining provides a reproducible basis for decisions on anti–PD-1 therapy in NSCLC.
참고문헌 (10)
- Guan J, "Programmed death ligand-1(PD-L1)expression in the programmed death receptor-1(PD-1)", PD-L1 blockade : a key player against various cancers, 2017, pp.141, 851~861
- Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
- Langer CJ, "Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer : a randomised, phase 2 cohort of the open-label KEYNOTE-021 study", Lancet Oncol, 17, pp.1497~1508 (2016)
- Gettinger S, "Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.2980~2987 (2016)
- Roach C, "Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer", Appl Immunohistochem Mol Morphol, 24, pp.392~397 (2016)
- Cree IA, "PD-L1 testing for lung cancer in the UK : recognizing the challenges for implementation", Histopathology, 69, pp.177~186 (2016)
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
- Rimm DL, "A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer", JAMA Oncol, 3, pp.1051~1058 (2017)
- Cooper WA, "Intra-and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer", Clin Cancer Res, 23, pp.4569~4577 (2017)
- Brunnström H, "PD-L1 immunohistochemistry in clinical diagnostics of lung cancer : interpathologist variability is higher than assay variability", Mod Pathol, 30, pp.1411~1421 (2017)